Guideline on dental management of pediatric patients receiving chemotherapy, hematopoietic cell transplantation, and/or radiation

Pediatric Dentistry

Volumn 35, Issue 5, 2013, Pages

[No Author Info available]

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT;

ADOLESCENT; ARTICLE; CHILD; DENTAL PROCEDURE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; METHODOLOGY; MOUTH DISEASE; NEOPLASM; PRACTICE GUIDELINE; PRESCHOOL CHILD; RADIOTHERAPY; STANDARD;

ADOLESCENT; ANTINEOPLASTIC AGENTS; CHILD; CHILD, PRESCHOOL; DENTAL CARE FOR CHILDREN; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; IMMUNOSUPPRESSION; MOUTH DISEASES; NEOPLASMS; RADIOTHERAPY;

EID: 84888611407     PISSN: 01641263     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (42)

1. National Cancer Institute: PDQ® Oral Complications of Chemotherapy and Head/Neck Radiation. Bethesda, MD: National Cancer Institute. Modified February 28, 2013. Available at: "http://cancer.gov/cancertopics/pdq/ supportivecare/oralcomplications/HealthProfessional." Accessed March 25, 2013.
2. Hong CH, Brennan MT, Lockhart PB. Incidence of acute oral sequelae in pediatric patients undergoing chemotherapy. Pediatr Dent 2009;31(5):420-5.
3. Scully C, Epstein JB. Oral health care for the cancer patient. Eur J Cancer B Oral Oncol 1996;32B(5):281-92.
4. Hong CH, Napeñas JJ, Hodgson BD, et al. A systematic review of dental disease in patients undergoing cancer therapy. Support Care Cancer 2010;18(8):1007-21.
5. th ed. St. Louis, Mo: Mosby-Elsevier; 2011:782-98.
6. Elad S, Thierer T, Bitan M, Shapira MY, Meyerowitz C. A decision analysis: The dental management of patients prior to hematology cytotoxic therapy or hematopoietic stem cell transplantation. Oral Oncol 2008;44(1):37-42.
7. Stiff PJ, Emmanouilides C, Bensinger WI, et al. Palifermin reduces patient-reported mouth and throat soreness and improves patient functioning in the hematopoietic stem-cell transplantation setting. J Clin Oncol 2006;24 (33):5186-93.
8. th ed. Oxford, UK: Wiley-Blackwell; 2009:1589-607.
9. Bavier AR. Nursing management of acute oral complications of cancer. Consensus Development Conference on Oral Complications of Cancer Therapies: Diagnosis, Prevention, and Treatment. National Cancer Institute Monograph No. 9. Bethesda, Md: National Institutes of Health; 1990:23-128.
10. th ed. St. Louis, Mo: Elsevier-Mosby; 2012: 459-92.
11. Semba SE, Mealy BL, Hallmon WW. Dentistry and the cancer patient: Part 2: Oral health management of the chemotherapy patient. Compend 1994;15(11):1378, 1380-7; quiz 1388.
12. nd ed. Philadelphia, Pa: WB Saunders Co; 1995:426-54.
13. Peterson DE, Bensadoun RJ, Roila F, ESMO Guidelines Working Group. Management of oral and gastrointestinal mucositis: ESMO Clinical Practice Guidelines. Ann Oncol 2011;22(Suppl 6):vi78-84.
14. Erratum in Ann Oncol 2012;23(3):810.
15. th Edition; Chicago, Ill. American Academy of Pediatric Dentistry; 2011:225-31.
16. da Fonseca MA. Pediatric bone marrow transplantation: Oral complications and recommendations for care. Pediatr Dent 1998;20(7):386-94.
17. da Fonseca MA. Long-term oral and craniofacial complications following pediatric bone marrow transplantation. Pediatr Dent 2000;22(1):57-62.
18. Hong CH, daFonseca M. Considerations in the pediatric population with cancer. Dent Clin N Am 2008;52(1): 155-81.
19. Baddour LM, Epstein AE, Erickson CC, et al. Update on cardiovascular implantable electronic device infections and their management. Circulation 2010;121(3):458-77.
20. Hong CH, Allred R, Napenas JJ, Brennan MT, Baddour LM, Lockhart PB. Antibiotic prophylaxis for dental procedures to prevent indwelling venous catheter-related infections. Am J Med 2010;123(12):1128-33.
21. Lockhart PB, Loven B, Brennan MT, Baddour LM, Levinson M. The evidence base for the efficiency of antibiotic prophylaxis in dental practice. J Am Dent Assoc 2007;138(4): 458-74.
22. Wilson W, Taubert KA, Gewitz M, et al. Prevention of infective endocarditis: Guidelines from the American Heart Association: A guideline from the American Heart Association Rheumatic Fever, Endocarditis, and Kawasaki Disease Committee, Council on Cardiovascular Disase in the Young, and the Council on Clinical Cardiology, Council on Cardiovascular Surgery and Anesthesia, and the Quality of Care and Outcomes Research Interdisciplinary Working Group. Circulation 2007;116(15):1736-54.
23. Erratum in: Circulation 2007;116(15):e376-7.
24. Ransier A, Epstein JB, Lunn R, Spinelli J. A combined analysis of a toothbrush, foam brush, and a chlorhexidinesoaked foam brush in maintaining oral hygiene. Canc Nurs 1995;18(5):393-6.
25. Peters E, Monopoli M, Woo SB, Sonis S. Assessment of the need for treatment of postendodontic asymptomatic periapical radiolucencies in bone marrow transplant recipients. Oral Surg Oral Med Oral Pathol 1993;76(1):45-8.
26. Sheller B, Williams B. Orthodontic management of patients with hematologic malignancies. Am J Orthod Dentofacial Orthop 1996;109(6):575-80.
27. Saad F, Brown JE, Van Poznak C, et al. Incidence, risk factors, and outcomes of osteonecrosis of the jaw: Integrated analysis from three blinded active-controlled phase III trials in cancer patients with bone metastases. Ann Oncol 2012;23(5):1341-7.
28. Kuhl S, Walter C, Acham S, Pfeffer R, Lambrecht JT. Bisphosphonate- related osteonecrosis of the jaws- A review. Oral Oncology 2012;48(10):938-47.
29. Dodson TB. Intravenous bisphosphonate therapy and bisphosphonate-related osteonecrosis of the jaws. J Oral Maxillofac Surg 2009;67(suppl 1):44-52.
30. American Academy of Pediatric Dentistry. Guideline on pediatric oral surgery. Pediatr Dent 2012;34(special issue): 264-271.
31. American Association of Oral and Maxillofacial Surgeons. White paper: Evidence based third molar surgery. November 10, 2011. Available at: "http://www.aaoms.org/docs/evidence-based-third-molar-surgery.pdf ". Accessed June 23, 2013.
32. Keefe DM, Schubert MM, Elting LS, et al. Updated clinical practice guidelines for the prevention and treatment of mucositis. Cancer 2007;109(5):820-831.
33. KuhnA, Porto FA, Miraglia P, Brunetto AL. Low-level infrared laser therapy in chemotherapy-induced oral mucositis: A randomized placebo-controlled trial in children. J Pediatr Hematol Oncol 2009;31(1):33-7.
34. Migliorati C, Hewson I, Lalla RV, et al. Systematic review of laser and other light therapy for the management of oral mucositis in cancer patients. Support Care Cancer 2013;21(1):333-41.
35. Clarkson JE, Worthington HV, Furness S, McCabe M, Khalid 660 T, Meyer S. Interventions for treating oral mucositis for patients with cancer receiving treatment (Review). Cochrane Database Syst Rev 2010;4(8): CD001973.
36. Gøtzche PC, Johansen HK. Nystatin prophylaxis and treatment in severely immunocompromised patients. Cochrane Database Syst Rev 2002;(2):CD002033.
37. Update in Cochrane Database Syst Rev 2002;(4):CD002033.
38. Nieuw Amerongen AV, Veerman EC. Current therapies for xerostomia and salivary gland hypofunction associated with cancer therapies. Support Care Cancer 2003;11 (4):226-31.
39. Euvrard S, Kanitakis J, Claudy A. Skin cancers after organ transplantation. N Engl J Med 2003;348(17): 1681-91.
40. Dahllöf G, Jönsson A, Ulmner M, Huggare J. Orthodontic treatment in long-term survivors after bone marrow transplantation. Am J Orthod Dentofacial Orthop 2001; 120(5):459-65.
41. Zahrowski JJ. Bisphosphonate treatment: An orthodontic concern for a proactive approach. Am J Orthod Dentofacial Orthop 2007;131(3):311-20.
42. Jensen SB, Pedersen AM, Vissink A, et al. A systematic review of salivary gland hypofunction and xerostomia induced by cancer therapies: Prevalence, severity, and impact on quality of life. Support Care Cancer 2010;18(8): 1039-60.